ZA202208343B - Daptomycin formulation - Google Patents

Daptomycin formulation

Info

Publication number
ZA202208343B
ZA202208343B ZA2022/08343A ZA202208343A ZA202208343B ZA 202208343 B ZA202208343 B ZA 202208343B ZA 2022/08343 A ZA2022/08343 A ZA 2022/08343A ZA 202208343 A ZA202208343 A ZA 202208343A ZA 202208343 B ZA202208343 B ZA 202208343B
Authority
ZA
South Africa
Prior art keywords
daptomycin
formulation
solid
daptomycin formulation
present disclosure
Prior art date
Application number
ZA2022/08343A
Other languages
English (en)
Inventor
Fumic Barbara
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of ZA202208343B publication Critical patent/ZA202208343B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2022/08343A 2020-02-28 2022-07-26 Daptomycin formulation ZA202208343B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982945P 2020-02-28 2020-02-28
PCT/EP2021/054841 WO2021170807A1 (en) 2020-02-28 2021-02-26 Daptomycin formulation

Publications (1)

Publication Number Publication Date
ZA202208343B true ZA202208343B (en) 2024-11-27

Family

ID=74797935

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/08343A ZA202208343B (en) 2020-02-28 2022-07-26 Daptomycin formulation

Country Status (9)

Country Link
US (1) US12629337B2 (cg-RX-API-DMAC7.html)
EP (1) EP4110303A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023516957A (cg-RX-API-DMAC7.html)
CN (2) CN118873500A (cg-RX-API-DMAC7.html)
AU (1) AU2021227095B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022015571A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022010378A (cg-RX-API-DMAC7.html)
WO (1) WO2021170807A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208343B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
WO2026111848A1 (en) * 2024-11-21 2026-05-28 MAIA Pharmaceuticals, Inc. Daptomycin compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2001267011B2 (en) 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
JP2003055256A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第xiii因子製剤
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US20110124551A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2013103801A1 (en) 2012-01-04 2013-07-11 Hospira, Inc. Pharmaceutical spray drying
NO2887953T3 (cg-RX-API-DMAC7.html) 2012-08-23 2018-03-10
PL4066849T3 (pl) 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
WO2016098009A1 (en) 2014-12-16 2016-06-23 Dr. Reddy’S Laboratories Limited Lyophilized injectable compositions of daptomycin
CN106943587B (zh) 2016-01-06 2021-06-22 山东新时代药业有限公司 一种注射用达托霉素冻干粉针及其制备工艺
US11759497B2 (en) * 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
GB201718888D0 (en) * 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation

Also Published As

Publication number Publication date
JP2025142200A (ja) 2025-09-30
US20230068866A1 (en) 2023-03-02
BR112022015571A2 (pt) 2022-09-27
AU2021227095A1 (en) 2022-08-25
EP4110303A1 (en) 2023-01-04
MX2022010378A (es) 2022-09-21
CN118873500A (zh) 2024-11-01
WO2021170807A1 (en) 2021-09-02
CN115038431B (zh) 2024-08-09
US12629337B2 (en) 2026-05-19
JP2023516957A (ja) 2023-04-21
AU2021227095B2 (en) 2024-02-22
CA3168727A1 (en) 2021-09-02
CN115038431A (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
MX2021015894A (es) Peptidos acetales para estabilizar enzimas.
PH12021551279A1 (en) Modified amine lipids
WO2020172420A3 (en) Stable anhydrous cleanser concentrate formulation and method of making same
MX2023009645A (es) Composiciones para preparar productos similares al huevo libres de animales.
ZA202309527B (en) Ionizable lipids and compositions for nucleic acid delivery
MX2022007275A (es) Composiciones de acidos biliares y compuestos de fenilbutirato.
MX2011012334A (es) Composicion y metodo para promover el crecimiento de raices de plantas.
MX2021006126A (es) Proceso de preparacion de una composicion tensioactiva a base de sal de ester de glicina betaina y composicion asi obtenida.
MX2022010378A (es) Formulacion de daptomicina.
MX2021006808A (es) Novedosa psicosa-6-fosfato fosfatasa, composicion para la produccion de psicosa que comprende la misma y procedimiento para la produccion de psicosa mediante el uso de la misma.
MY207295A (en) Method for preparing a composition comprising cetylated fatty acids
MX2025005727A (es) Composiciones para el cuidado bucal
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
ZA202105901B (en) Afabicin formulation, method for making the same
EA201692454A1 (ru) Твердая фосфатная соль и способ ее получения
MX2019006122A (es) Metodo de hornear.
MX392143B (es) Composiciones cosméticas para el cuidado de la piel.
MX2021011553A (es) Producto para el cuidado bucal y metodos para uso y fabricacion de este.
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
WO2019215373A3 (es) Procedimiento para la síntesis de poliéteres
EA202091007A1 (ru) Способ снижения времени восстановления высушенных распылением белковых составов
PH12022552789A1 (en) Laminarin based formulation for agricultural applications
AU2018347511A8 (en) Periodontitis vaccine and related compositions and method of use
PH12017502323A1 (en) Novel xylanase
MX2019006310A (es) Procedimiento para la preparacion de una formulacion de 2-[(3-aminopropil)amino]etanotiol liofilizado.